Work

Dividing and conquering the variation among variants in EML4-ALK lung cancer

Year: 2017

Type: article

Abstract: Activating gene rearrangements in the anaplastic lymphoma kinase are present in approximately 2–7% of lung adenocarcinomas (ALK + cancers) (1,2). Patients with ALK + lung adenocarcinoma often benefit from treatment with an ALK tyrosine kinase inhibitor (TKI), such as crizotinib, ceritinib, and alectinib (2). However, acquired ALK TKI resistance remains an obstacle to long-term patient survival in patients who do respond to initial therapy and a distinct subset of ALK + patients fails to experience an initial tumor regression, exhibiting intrinsic resistance (2). Identifying the basis of both innate and acquired resistance is essential to improve clinical outcomes.

Source: Translational Cancer Research

DOI: 10.21037/tcr.2017.03.25

Author: Trever G. Bivona

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: National Cancer Institute